Int. J. Mol. Sci. 2012, 13(9), 11288-11311; doi:10.3390/ijms130911288

Asymmetric Dimethylarginine, Endothelial Dysfunction and Renal Disease

* email and email
Received: 2 August 2012; in revised form: 28 August 2012 / Accepted: 3 September 2012 / Published: 10 September 2012
(This article belongs to the Special Issue ADMA and Nitrergic System)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: L-Arginine (Arg) is oxidized to L-citrulline and nitric oxide (NO) by the action of endothelial nitric oxide synthase (NOS). In contrast, protein-incorporated Arg residues can be methylated with subsequent proteolysis giving rise to methylarginine compounds, such as asymmetric dimethylarginine (ADMA) that competes with Arg for binding to NOS. Most ADMA is degraded by dimethylarginine dimethyaminohydrolase (DDAH), distributed widely throughout the body and regulates ADMA levels and, therefore, NO synthesis. In recent years, several studies have suggested that increased ADMA levels are a marker of atherosclerotic change, and can be used to assess cardiovascular risk, consistent with ADMA being predominantly absorbed by endothelial cells. NO is an important messenger molecule involved in numerous biological processes, and its activity is essential to understand both pathogenic and therapeutic mechanisms in kidney disease and renal transplantation. NO production is reduced in renal patients because of their elevated ADMA levels with associated reduced DDAH activity. These factors contribute to endothelial dysfunction, oxidative stress and the progression of renal damage, but there are treatments that may effectively reduce ADMA levels in patients with kidney disease. Available data on ADMA levels in controls and renal patients, both in adults and children, also are summarized in this review.
Keywords: asymmetric dimethylarginine (ADMA); arginine (Arg); children; dimethylarginine dimethylaminohydrolase (DDAH); endothelial dysfunction; kidney; methylarginines; nitric oxide; oxidative stress; renal failure
PDF Full-text Download PDF Full-Text [633 KB, uploaded 19 June 2014 04:26 CEST]

Export to BibTeX |

MDPI and ACS Style

Aldámiz-Echevarría, L.; Andrade, F. Asymmetric Dimethylarginine, Endothelial Dysfunction and Renal Disease. Int. J. Mol. Sci. 2012, 13, 11288-11311.

AMA Style

Aldámiz-Echevarría L, Andrade F. Asymmetric Dimethylarginine, Endothelial Dysfunction and Renal Disease. International Journal of Molecular Sciences. 2012; 13(9):11288-11311.

Chicago/Turabian Style

Aldámiz-Echevarría, Luis; Andrade, Fernando. 2012. "Asymmetric Dimethylarginine, Endothelial Dysfunction and Renal Disease." Int. J. Mol. Sci. 13, no. 9: 11288-11311.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert